Baudax Bio Regains Compliance with NASDAQ Listing Requirements
March 07, 2022 08:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings,...
Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO®
March 02, 2022 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today...
Baudax Bio Announces Pricing of $10.0 Million Public Offering
February 24, 2022 23:23 ET
|
Baudax Bio, Inc.
MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative...
Baudax Bio Announces Proposed Public Offering of Securities
February 24, 2022 16:40 ET
|
Baudax Bio, Inc.
MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative...
Baudax Bio Announces 1-for-35 Reverse Stock Split
February 15, 2022 20:29 ET
|
Baudax Bio, Inc.
MALVERN, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today...
Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
January 04, 2022 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today...
Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 31, 2021 16:05 ET
|
Baudax Bio, Inc.
MALVERN, Pa., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care...
Baudax Bio Announces $4.2 Million Registered Direct Offering
December 28, 2021 08:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care...
Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today...
Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000
November 11, 2021 07:00 ET
|
Baudax Bio, Inc.
BX-1000 Completes Dose-Escalation Study; Was Generally Well Tolerated and Rapidly Achieved Muscle Paralysis, Along with Complete Spontaneous Recovery BX-2000 and BX-3000 to Advance Into Clinical...